Condition: ccRCC · Renal Cell Carcinoma (Kidney Cancer) · Renal Cell Carcinoma (RCC) · Sponsor: Telix Pharmaceuticals (Innovations) Pty Limited
Multicenter Phase 3 study of 177Lu-TLX250 in adult participants with CAIX-expressing advanced, relapsed or recurrent clear cell renal cell carcinoma (ccRCC). Part 1 will evaluate two dosing regimens to determine the recommended Phase 3 dose (RP3D). Part 2 will compare 177Lu-TLX250 with investigator's choice of monotherapy aligned with Australian standard-of-care.
This description comes directly from the study's public registry record.
Prson Gautam, PhD · 19196508158 · prson.gautam@telixpharma.com
Lily Nahidi, PhD · lily.nahidi@telixpharma.com
Always discuss trial participation with your own doctor first.
| Westmead Hospital | Sydney, New South Wales, Australia | Not Yet Recruiting |
| Wollongong Hospital | Wollongong, New South Wales, Australia | Not Yet Recruiting |
| Austin Health | Heidelberg, Victoria, Australia | Not Yet Recruiting |
| Melbourne Theranostic Innovation Centre (MTIC) | Melbourne N., Victoria, Australia | Not Yet Recruiting |
| GenesisCare, Fiona Stanley Hospital (Murdoch) | Murdoch, Washington, Australia | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07197580